Literature DB >> 8387918

Mutational analysis of a type II topoisomerase cleavage site: distinct requirements for enzyme and inhibitors.

C H Freudenreich1, K N Kreuzer.   

Abstract

We have analyzed the DNA sequence requirements for cleavage of a 30 bp oligonucleotide that contains a strong bacteriophage T4 type II topoisomerase site. A novel method was used to generate substrates with each of the four nucleotides at 10 positions surrounding the cleavage site, and mutant substrates were also prepared for the four internal positions of the staggered cleavage site. The substrates were tested for cleavage in the presence of several inhibitors that induce enzyme-mediated cleavage: four antitumor agents of different classes (an aminoacridine, a substituted anthraquinone, an ellipticine derivative and an epipodophyllotoxin) and one antibacterial quinolone. At eight nucleotide positions flanking the cleavage site, the same preferred bases were found regardless of which inhibitor was present. These preferred bases show dyad symmetry with respect to the cleavage site, indicating that both protomers of the topoisomerase homodimer interact with DNA in an analogous manner. In addition, we found that the preferred bases on the 5' side of each cleaved phosphodiester bond are highly specific to the inhibitor used in the cleavage reaction. These results strongly suggest that the inhibitors interact directly with the DNA bases at the cleavage site, placing the inhibitor binding site precisely at the site of DNA cleavage.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8387918      PMCID: PMC413430          DOI: 10.1002/j.1460-2075.1993.tb05857.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  51 in total

1.  Purification and characterization of an altered topoisomerase II from a drug-resistant Chinese hamster ovary cell line.

Authors:  D M Sullivan; M D Latham; T C Rowe; W E Ross
Journal:  Biochemistry       Date:  1989-06-27       Impact factor: 3.162

2.  Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug--DNA binding model.

Authors:  L L Shen; L A Mitscher; P N Sharma; T J O'Donnell; D W Chu; C S Cooper; T Rosen; A G Pernet
Journal:  Biochemistry       Date:  1989-05-02       Impact factor: 3.162

3.  Double-stranded DNA cleavage/religation reaction of eukaryotic topoisomerase II: evidence for a nicked DNA intermediate.

Authors:  E L Zechiedrich; K Christiansen; A H Andersen; O Westergaard; N Osheroff
Journal:  Biochemistry       Date:  1989-07-25       Impact factor: 3.162

Review 4.  Topoisomerase-targeting antitumor drugs.

Authors:  P D'Arpa; L F Liu
Journal:  Biochim Biophys Acta       Date:  1989-12-17

5.  Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity.

Authors:  G Capranico; F Zunino; K W Kohn; Y Pommier
Journal:  Biochemistry       Date:  1990-01-16       Impact factor: 3.162

6.  Design of DNA intercalators to overcome topoisomerase II-mediated multidrug resistance.

Authors:  B C Baguley; K M Holdaway; L M Fray
Journal:  J Natl Cancer Inst       Date:  1990-03-07       Impact factor: 13.506

7.  Nuclease protection by Drosophila DNA topoisomerase II. Enzyme/DNA contacts at the strong topoisomerase II cleavage sites.

Authors:  M P Lee; M Sander; T Hsieh
Journal:  J Biol Chem       Date:  1989-12-25       Impact factor: 5.157

8.  Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II.

Authors:  L A Zwelling; M Hinds; D Chan; J Mayes; K L Sie; E Parker; L Silberman; A Radcliffe; M Beran; M Blick
Journal:  J Biol Chem       Date:  1989-10-05       Impact factor: 5.157

9.  High field 1H-NMR analysis of the 1:1 intercalation complex of the antitumor agent mitoxantrone and the DNA duplex [d(CpGpCpG)].

Authors:  J W Lown; C C Hanstock
Journal:  J Biomol Struct Dyn       Date:  1985-06

10.  Topoisomerase II is a structural component of mitotic chromosome scaffolds.

Authors:  W C Earnshaw; B Halligan; C A Cooke; M M Heck; L F Liu
Journal:  J Cell Biol       Date:  1985-05       Impact factor: 10.539

View more
  14 in total

1.  Position-specific effect of ribonucleotides on the cleavage activity of human topoisomerase II.

Authors:  Y Wang; A Thyssen; O Westergaard; A H Andersen
Journal:  Nucleic Acids Res       Date:  2000-12-15       Impact factor: 16.971

2.  An antitumor drug-induced topoisomerase cleavage complex blocks a bacteriophage T4 replication fork in vivo.

Authors:  G Hong; K N Kreuzer
Journal:  Mol Cell Biol       Date:  2000-01       Impact factor: 4.272

3.  Topoisomerase II-mediated site-directed alkylation of DNA by psorospermin and its use in mapping other topoisomerase II poison binding sites.

Authors:  Y Kwok; Q Zeng; L H Hurley
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

4.  In the presence of subunit A inhibitors DNA gyrase cleaves DNA fragments as short as 20 bp at specific sites.

Authors:  H Gmünder; K Kuratli; W Keck
Journal:  Nucleic Acids Res       Date:  1997-02-01       Impact factor: 16.971

Review 5.  Bacteriophage T4 genome.

Authors:  Eric S Miller; Elizabeth Kutter; Gisela Mosig; Fumio Arisaka; Takashi Kunisawa; Wolfgang Rüger
Journal:  Microbiol Mol Biol Rev       Date:  2003-03       Impact factor: 11.056

6.  Base mutation analysis of topoisomerase II-idarubicin-DNA ternary complex formation. Evidence for enzyme subunit cooperativity in DNA cleavage.

Authors:  M Bigioni; F Zunino; G Capranico
Journal:  Nucleic Acids Res       Date:  1994-06-25       Impact factor: 16.971

7.  Disruption of a topoisomerase-DNA cleavage complex by a DNA helicase.

Authors:  M T Howard; S H Neece; S W Matson; K N Kreuzer
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-06       Impact factor: 11.205

Review 8.  Structure and function of type II DNA topoisomerases.

Authors:  P M Watt; I D Hickson
Journal:  Biochem J       Date:  1994-11-01       Impact factor: 3.857

9.  Localization of an aminoacridine antitumor agent in a type II topoisomerase-DNA complex.

Authors:  C H Freudenreich; K N Kreuzer
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

10.  CP-115,953 stimulates cytokine production by lymphocytes.

Authors:  K Riesbeck; A Forsgren
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.